Insights from 2024 ESMO GI Annual Meeting

 

Insights from 2024 ESMO GI Annual Meeting
J

ESMO GI 2024 Insights: CodeBreaK 300 - Patient-Reported Tolerability of Sotorasib & Panitumumab vs. Trifluridine/Tipiracil or Regorafenib in mCRC

By Insights from 2024 ESMO GI Annual Meeting FEATURING Julien Taieb
By Insights from 2024 ESMO GI Annual Meeting FEATURING Julien Taieb
155 views
July 3, 2024
0 Comments
Login to view comments. Click here to Login
Videos
10:48
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: Is It Time For a New Staging System For Colon…

Feat. A. Dasari
05:28
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: Updates on Treatment of Stage II CRC

Feat. E. Martinelli
07:47
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: Ten Years of Improvement in the Treatment of …

Feat. S. L. Chan
07:59
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: DEEPER Trial - m-FOLFOXIRI + Cetuximab vs. Be…

Feat. Y. Sunakawa
10:28
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: Durvalumab + Chemo in Biliary Tract Cancer - …

Feat. D. Oh
25:02
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Feat. T. Seufferlein
03:33
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Insights: CodeBreaK 300 - Patient-Reported Tolerability…

Feat. J. Taieb
04:35
Insights from 2024 ESMO GI Annual Meeting

ESMO GI 2024 Summary: Combined Analysis of ctDNA and Immunoscore in …

Feat. J. Taieb